Search research articles
Contact Us
Filters
Showing results (21-30 of 93) with videos related to
Page
of 10
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 3, 2006
18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy
Wei Chen, Daniel H S Silverman, Sibylle Delaloye, et al.
Neuro-Oncology
|
January 27, 2016
Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy
Frank Saran, Olivier L Chinot, Roger Henriksson, et al.
Neuro-Oncology
|
March 24, 2016
Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio
Olivier L Chinot, Ryo Nishikawa, Warren Mason, et al.
Neuro-Oncology
|
August 13, 2016
Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma
Wolfgang Wick, Olivier L Chinot, Martin Bendszus, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 11, 2012
Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective
Franziska Walter, Timothy Cloughesy, Martin A Walter, et al.
Neuro-Oncology
|
December 6, 2013
Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients
Ken Herrmann, Johannes Czernin, Timothy Cloughesy, et al.
Cancer Research
|
September 18, 2004
Gene expression profiling of gliomas strongly predicts survival
William A Freije, F Edmundo Castro-Vargas, Zixing Fang, et al.
Investigational New Drugs
|
May 22, 2020
A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma
David A Reardon, Annick Desjardins, Olivier Rixe, et al.
Cancer Chemotherapy and Pharmacology
|
June 3, 2019
Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII
Mark Rosenthal, Richard Curry, David A Reardon, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 7, 2005
Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG
Wei Chen, Timothy Cloughesy, Nirav Kamdar, et al.
Page
of 10
Search research articles
Search
Showing results (21-30 of 93) with videos related to
Sort By:
Page
of 10
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 3, 2006
18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy
Wei Chen, Daniel H S Silverman, Sibylle Delaloye, et al.
Neuro-Oncology
|
January 27, 2016
Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy
Frank Saran, Olivier L Chinot, Roger Henriksson, et al.
Neuro-Oncology
|
March 24, 2016
Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio
Olivier L Chinot, Ryo Nishikawa, Warren Mason, et al.
Neuro-Oncology
|
August 13, 2016
Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma
Wolfgang Wick, Olivier L Chinot, Martin Bendszus, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 11, 2012
Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective
Franziska Walter, Timothy Cloughesy, Martin A Walter, et al.
Neuro-Oncology
|
December 6, 2013
Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients
Ken Herrmann, Johannes Czernin, Timothy Cloughesy, et al.
Cancer Research
|
September 18, 2004
Gene expression profiling of gliomas strongly predicts survival
William A Freije, F Edmundo Castro-Vargas, Zixing Fang, et al.
Investigational New Drugs
|
May 22, 2020
A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma
David A Reardon, Annick Desjardins, Olivier Rixe, et al.
Cancer Chemotherapy and Pharmacology
|
June 3, 2019
Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII
Mark Rosenthal, Richard Curry, David A Reardon, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 7, 2005
Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG
Wei Chen, Timothy Cloughesy, Nirav Kamdar, et al.
Page
of 10